Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Revisão |
語言: | 英语 |
出版: |
2023
|
在線閱讀: | https://doi.org/10.1002/art.42538 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|